<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The activation of protooncogenes (ras, fms and myc genes) by point mutations in <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> are described in this review </plain></SENT>
<SENT sid="1" pm="."><plain>Ras mutations are found in a variety of human <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> at codon 12, 13, and 61 </plain></SENT>
<SENT sid="2" pm="."><plain>Generally, N-ras mutations are frequent in <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Fms mutation at codon 301 and 969, which are seen in 10 to 20% cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, increase tyrosine kinase activity of the fms products </plain></SENT>
<SENT sid="4" pm="."><plain>Ras and fms mutations are postulated to influence <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> at rather early stages </plain></SENT>
<SENT sid="5" pm="."><plain>Burkitt <z:hpo ids='HP_0002665'>lymphomas</z:hpo> are characterized by specific chromosomal translocations between c-myc gene and one of the immunoglobulin genes </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, mutations in the 3' border of the exon 1 of c-myc are frequent, and may play an additional role in pathogenesis of Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>